"name","id","description","uuid:ID","text","instanceType","label"
"OBJ1","Objective_1","Main objective","f77c5175-630f-4155-ba21-6b4768e9c983","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective",""
"OBJ2","Objective_2","Safety","4c6becdc-28a1-4f57-afb3-372398249ec3","To document the safety profile of the xanomeline TTS.","Objective",""
"OBJ3","Objective_3","Behaviour","a886998a-d2ed-48ef-ad8f-f7c06954f890","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective",""
